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Abstract
There is an intimate interplay between cellular metabolism and the pathophysiology of disease. 
Mitochondria are essential to maintaining and regulating metabolic function of cells and organs. 
Mitochondrial dysfunction is implicated in diverse diseases, such as cardiovascular disease, 
diabetes and metabolic syndrome, neurodegeneration, cancer and aging. Multiple reversible post-
translational protein modifications are located in the mitochondria that are responsive to nutrient 
availability and redox conditions, and which can act in protein-protein interactions to modify 
diverse mitochondrial functions. Included in this are physiologic redox signaling via reactive 
oxygen and nitrogen species, phosphorylation, O-GlcNAcylation, acetylation, and succinylation, 
among others. With the advent of mass proteomic screening techniques, there has been a vast 
increase in the array of known mitochondrial post-translational modifications and their protein 
targets. The functional significance of these processes in disease etiology, and the pathologic 
response to their disruption, are still under investigation. However, many of these reversible 
modifications act as regulatory mechanisms in mitochondria and show promise for mitochondrial-
targeted therapeutic strategies. This review addresses the current knowledge of post-translational 
processing and signaling mechanisms in mitochondria, and their implications in health and 
disease.
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Introduction
Abnormal cellular metabolism and pathology of human disease are intimately linked[1]. 
Mitochondria are an integral component of normal cellular function, and are central to 
Corresponding author: R. Mark Payne, Wells Center for Pediatric Research, 1044 W. Walnut St., Room R4-302b, Indianapolis, IN 
46202, rpayne@iu.edu, Phone: 317-278-6239. 
HHS Public Access
Author manuscript
Cell Mol Life Sci. Author manuscript; available in PMC 2017 November 01.
Published in final edited form as:
Cell Mol Life Sci. 2016 November ; 73(21): 4063–4073. doi:10.1007/s00018-016-2280-4.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
maintaining and regulating nutrient flow through metabolic pathways. Mitochondrial 
dysfunction itself is associated with a number of diseases, including cardiovascular disease, 
diabetes and the metabolic syndrome, neurodegenerative diseases, cancer and aging[2–7]. 
Hereditary mitochondrial disorders result in multi-organ dysfunction, signifying the 
importance of mitochondrial function across tissue types. Because mitochondria provide the 
vast majority of ATP for cellular activity, mitochondrial dysfunction likely plays a central 
role in disordered cellular metabolism, thus implicating it as an important pathologic 
contributor [8–11].
Recently, the discovery that reversible post-translational modifications of proteins are 
involved in regulating core metabolic processes has generated a tremendous amount of 
interest [12–17]. It is well known that mitochondrial proteins can undergo post-translational 
protein modifications similar to nuclear and cytoplasmic proteins. The discovery and 
knowledge of the mechanisms of mitochondrial protein modifications, and identification of 
novel target proteins, has exploded recently with the advent of mass spectrometry and 
analysis capabilities. From this, it is clear that post-translational modifications in 
mitochondria are abundant and diverse, and that many of these modifications alter 
mitochondrial function (Table 1) [18].
Post-translational protein modifications typically provide for intra- and inter-cellular 
signaling and regulation of chemical networks within the cell. As such, many mitochondrial 
post-translational modifications have been found to be involved in signal transduction 
pathways modulating mitochondrial energy generation, apoptosis, autophagy, metabolism, 
and tissue response to ischemic injury. Due to the vast array of post-translational 
mechanisms and targets, this is not a comprehensive review, and is not meant to contain a 
complete list of post-translational modification and target protein in the mitochondrial 
milieu subjected to modification. We will focus our discussion on the main post-translational 
modifications currently characterized in mitochondria, the mechanism by which they are 
considered to influence cellular metabolism and function, and their functional relevance to 
human disease.
Phosphorylation
One of the oldest known signaling mechanism used by mitochondria to regulate metabolism 
is targeting metabolic proteins for reversible phosphorylation. In the 1970s, the activity of 
pyruvate dehydrogenase (PDH) was found to be modulated by a phosphorylation reaction by 
a PDH-specific kinase and phosphatase to activate or inactive the enzymatic activity in 
response to cellular energy status[19]. More recently, however, an increasing number of 
phosphorylated substrates have been identified with diverse roles within mitochondria. The 
majority of phosphorylation events in the mitochondria are via Src-kinases, non-receptor 
tyrosine kinases that act by phosphorylating tyrosine residues on protein substrates [17, 20, 
21].
Mitochondrial ATP production, generated by OXPHOS via the components of the electron 
transport chain (ETC), is regulated by reversible phosphorylation (see Figure 1 for a review 
of the ETC). Phosphorylation of ETC Complex I (CI) subunit NDUFB10 decreases its 
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activity, while phosphorylation of NDUSF4 increases its activity [22–24]. Complex III 
(CIII) subunits I and II are reversibly phosphorylated by Src-kinases that decreases the 
activity of CIII. The Rieske protein of CIII is also reversibly phosphorylated, although with 
indeterminate effect [25, 26]. Complex IV (CIV) contains multiple sites of reversible 
phosphorylation with varying effects. CIV subunit IV-1(CIV-I) and IV (CIV-IV) are 
phosphorylated by protein kinase A (PKA), which increases activity of CIV [27, 28]. 
Phosphorylation of CIV subunit II (CIV-II) by Src-kinases increases CIV activity [26, 29], 
while phosphorylation of CIV-II by EGFR decreases CIV activity [30, 31], and 
phosphorylation of CIV-II by ERBb2 decreases mitochondrial respiration and increases 
glycolysis [31]. Finally, phosphorylation of Complex V (CV or ATP synthase), the enzyme 
responsible for harnessing the energy in the electrochemical gradient to synthesize ATP, by 
Src-kinases decreases its activity [26, 32].
Phosphorylation of proteins in the mitochondria also acts to mediate cell death signals. 
Phosphorylation of the outer mitochondrial membrane protein, voltage-dependent anion 
channel (VDAC) up-regulates its expression and induces cellular apoptosis [33]. 
Phosphorylation signaling cascades have also been implicated in controlling mitochondrial 
permeability transition pore (mPTP) mediated apoptosis [32].
The relevance of mitochondrial protein phosphorylation in disease is illustrated by its role in 
cardiovascular events. For instance, the mitochondrial protein STAT3 is involved in cellular 
respiration. Phosphorylation of STAT3 in response to cardiac ischemia and reperfusion was 
demonstrated to be important in maintaining ETC CI and CII respiratory activity [34]. 
Increased phosphorylation in ischemic post-conditioning improved CI respiration and 
inhibited permeability transition pore opening, and was associated with a reduction in infarct 
size [35, 36].
Redox signaling
For many years, oxidative modification in the cell has been considered detrimental to 
cellular function. Recently, it has become clear that oxidative reactions play a fundamental 
role in cellular response to redox balance to influence protein-protein interactions and 
cellular signaling networks. In fact, under physiologic conditions, redox-active molecules 
exert reversible oxidative post-translational modifications to facilitate signal transduction 
and modulate cellular function in response to the redox state of the cell [37–42]. Redox-
related post-translational modification used in cellular signaling warrants its own review, and 
indeed, this topic has been comprehensively reviewed recently [40, 43]. Here, we will focus 
on mitochondrial reversible post-translational modifications that are used as protein 
signaling with implications in human disease and pathology.
Redox reactions are central to mitochondrial mechanisms of nutrient respiratory metabolism 
and OXPHOS. In a healthy cell, the redox state is kept carefully in check by 
counterbalancing reactive oxygen (ROS) or nitrogen species (RNS) production by 
neutralization with antioxidant defense mechanisms. However, perturbations in the normal 
redox balance results in accumulation of ROS and RNS leading to oxidative stress and 
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cellular damage through generation of the highly reactive and toxic OH−, and ONOO−, 
causing irreversible protein modifications.
Physiologic levels of ROS (in the form of O2− and H2O2) act as signaling molecules in the 
mitochondria, for example, by reacting with protein thiols to form reversible modifications 
on target proteins. Such oxidative modifications can act as messengers to signal changes in 
redox balance and allow the cell to modulate metabolism accordingly[44]. This has 
physiologic significance in the cardiovascular system, where mitochondrial production of 
H2O2 couples myocardial oxygen consumption to coronary blood flow [45]. Redox-related 
protein modifications include S-oxidation (sulfenylation and sulfinylation), S-nitrosylation, 
and S-glutathionylation.
Nitrosylation is a post-translational modification in which reactive nitrogen species (RNS) 
perform selective modification of protein cysteine residues to form S-nitrosocysteine (S-
nitrosylation of cysteine residues). These reversible reactions occur under normal 
physiologic redox conditions in the cell and act as signals to modulate a diverse array of 
cellular function[18, 46–50]. A recent mass spectrometry-based approach to identifying 
nitrosylated proteins in the mouse revealed that over half of the nitrosylated proteins 
identified in the heart, and approximately a quarter in the brain, kidney, liver, lung, and 
thymus, were localized to mitochondria [51]. This reveals the heavy use of nitrosylation 
protein signaling in mitochondrially-dependent, metabolically active tissues.
In the mitochondria, nitric oxide (NO) can form nitrosyl or nitrite adducts with CIV to act 
directly as a competitive and reversible inhibitor to regulate mitochondrial respiration in 
response to fluctuations in redox and energy state. NO and oxygen compete for binding to 
the active center of CIV. In relative hypoxia, NO binding inhibits CIV activity and slows the 
rate of OXPHOS and ROS production [37, 52, 53]. Similarly, S-nitrosylation of ATP 
synthase inhibits its activity [46].
Mitochondrial metabolic enzymes that have been identified as targets of nitrosylation 
include those involved in fatty acid oxidation, including very long chain acyl–coenzyme A 
(CoA) dehydrogenase (VLCAD), and components of the tricarboxylic (TCA) cycle. 
VLCAD increases its enzymatic activity in response to S-nitrosylation[51]. Nitrosylation 
also plays a role in mitochondria-regulated cell death. S-nitrosylation of cyclophilin D, 
simulating protein modification under low levels of nitric oxide, inhibits opening of the 
mPTP and prevents induction of apoptosis [54, 55]. Similarly, NO modification of 
mitochondrial caspase-3 results in inhibition of inducible cell death pathway [56]. These 
findings have mechanistic implications for protein modifications acting as mediators in 
cardiomyocyte apoptosis in response to ischemic insult.
Clear pathophysiologic relevance is demonstrated by S-nitrosylation protection from 
myocardial ischemia-reperfusion injury [57, 58]. Specific mechanisms may involve 
reversible S-nitrosylation of CI, which was shown to exhibit a cardioprotective effect by 
reducing infarct size in myocardium exposed to ischemic insult. This resulted in reduction in 
activity of CI and decreased ROS generation, which would be expected to contribute to the 
mechanism of cardioprotection [39, 59, 60].
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O-GlcNAcylation
O-linked beta-N-acetylglucosamine (O-GlcNAc) attachment to Ser/Thr residues (O-
GlcNAcylation) is a nutrient-sensitive and reversible post-translational protein modification 
employed in cellular signaling. It is almost as wide spread and varied as phosphorylation, 
and in fact, phosphorylation and O-GlcNAcylation appear to be intricately linked along 
multiple cellular pathways and play interrelated roles in pathological states [61–63]. Based 
on large scale proteomic techniques, the number of known O-GlcNAcylation protein targets 
has exploded in recent years, with now more than 4000 identified throughout the cell [64].
The enzyme O-GlcNAc transferase (OGT) is responsible for adding O-GlcNAc to target 
proteins, and the enzyme O-GlcNAcase (OGA) catalyzes its removal. Both an isoform of 
OGT (mOGT) and OGA have been found in mitochondria, and a specific mitochondrial 
transporter has been identified that imports the donor substrate (UDP-GlcNAc) [65–67], 
providing evidence for the functional significance of O-GlcNAcylation as a regulatory PTM 
in mitochondria. O-GlcNAc mitochondrial protein modification is targeted to enzymes 
involved in diverse processes from mitochondrial metabolism of the TCA cycle, electron 
transport chain and lipid metabolism, as well as proteins involved in mitochondrial division 
and apoptosis signaling [68, 69]. Mounting evidence suggests that the expression and 
activity of the nutrient-sensitive mOGT is important in regulating mitochondrial metabolism, 
as well as mitochondrial apoptosis via protein modifications [66, 70–74].
Of particular relevance to how metabolic dysfunction impacts normal post-translational 
modifications is the effect of prolonged nutrient excess on O-GlcNAcylation. Aberrantly 
high levels of glucose and fatty acids result in elevations in O-GlcNAcylation, as occurs in 
diabetes [71]. Increased levels of O-GlcNAcylation in diabetes has been implicated in 
widespread cellular dysfunction. Specifically, abnormalities in O-GlcNAcylation have been 
shown to be associated with impaired respiratory activity, decreased ATP content, and lower 
mitochondrial calcium [71, 73]. While not mitochondria-specific, per se, decreased O-
GlcNAcylation has shown to improve cardiac function in diabetic mice [75, 76]. This 
provides evidence that disordered O-GlcNAc protein modification appears to pathologically 
relevant to the mitochondrial dysfunction associated with the hyperglycemia of diabetes and 
its associated complications.
Lysine Acetylation
Sirtuins are a family of NAD+-dependent enzymes that regulate diverse biological functions. 
There are seven identified sirtuins, sirtuin 1–7, with three located in mitochondria, sirtuin 3–
5. Sirtuin 3 (SIRT3) is a deacetylase that responds to cellular energy status and utilizes an 
“acetylation switch” to modify protein function [77–79]. SIRT3 catalyzes the removal of 
acetyl groups from lysine side chains. Mitochondria appear to utilize lysine acetylation-
deacetylation of proteins to respond quickly to metabolic cues and thus, represents an 
important post translational mechanism for maintaining normal mitochondrial function and 
metabolism [79]. While early reports suggested the presence of an acetyltransferase 
mechanism [80], definitive identification of such a counter enzyme has not been successful. 
Rather, acetylation appears to be non-enzymatic, and related to acetyl CoA availability and 
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reactivity in the mitochondrial matrix [81, 82]. Sirtuin 4 (SIRT4) has demonstrated only 
weak deacetylase activity, and while the primary activity of SIRT4 remains largely 
uncharacterized, it has been shown to have mono-ADP-ribosylase activity [83, 84]. SIRT5 is 
discussed below.
SIRT3 targets enzymes that typically activate in response to removal of acetyl groups, and 
which are important to energy generation and utilization, such as long-chain acyl-CoA 
dehydrogenase (LCAD) [85, 86], pyruvate dehydrogenase (PDH) [87], acetyl-CoA 
synthetase 2 (AceCS2) [88], Isocitrate dehydrogenase 2 (IDH2) [89], and ETC complexes I–
III and CV (ATP synthase)[90–93], among others important to core metabolic processes 
(Figure 2) [94–97]. SIRT3 deacetylation has been shown to increase the activity of CI-
NDUFA9, CII-SDHA and ATP synthase [90, 91, 98, 99]. Fatty acid metabolism is regulated 
by deacetylation of AceCS2, which stimulates conversion of acetate into acetyl CoA [88, 
100], 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2) stimulating ketogenesis 
[101], and LCAD, stimulating fatty acid oxidation [86]. Malonyl CoA decarboxylase (MCD) 
is the only known substrate of SIRT4 deacetylase activity. Deacetylation inhibits MCD, thus 
inhibiting fatty acid oxidation and promoting lipogenesis [102]. Carbohydrate metabolism is 
regulated by deacetylation of cyclophilin D, releasing hexokinase 2 and causing a decrease 
in glycolysis [103], and PDH, which activates in response to deacetylation by SIRT3 [104].
SIRT3 also targets proteins that maintain redox balance and provide protection from 
oxidative damage. Deacetylation of superoxide dismutase 2 (SOD2) increases its activity as 
a free radical scavenger [105–107]. IDH2 responds to deacetylation with increased 
metabolic activity in the TCA cycle, and is also associated with protection from oxidative 
stress-related cell death [89]. Mitochondrial permeability transition pore-mediated apoptosis 
is also regulated by deacetylation, with deacetylation by SIRT3 inhibiting pore opening[95]. 
Mitochondrial OGG1 (8-Oxoguanine glycosylase) stabilizes in response to deacetylation by 
SIRT3 under oxidative stress and protects from intrinsic apoptosis [108].
Particular functional relevance of acetylation post-translational modification is in 
cardiovascular disease. Given the heart’s reliance on functional mitochondrial metabolism 
due to its constant demand for energy substrates, it is not surprising that SIRT3 is emerging 
as an important player in cardiovascular disease[109]. For example, SIRT3 has been shown 
to protect against oxidative stress [110–112], attenuate fatty acid accumulation in the heart 
[113] and prevent development of stress-induced cardiac hypertrophy [114]. Recent reports 
demonstrate that mice lacking SIRT3 have mitochondrial dysfunction resulting in 
myocardial energy loss, develop hypertrophy and fibrosis in response to mechanical stress 
[115], and are more susceptible to the detrimental effects of ischemia/reperfusion injury 
[116].
Lysine Acylation (Succinylation, Glutarylation, Malonylation)
Most recently, protein modification by lysine malonylation, succinylation, and glutarylation, 
and their regulation by the NAD+-dependent sirtuin, SIRT5, have gained greater interest. 
The functional characterization of each of these post-translational modifications is still being 
investigated. SIRT5 catalyzes deacylation (desuccinylation, deglutarylation and 
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demalonylation) of mitochondrial proteins, and dynamically regulates these pathways. 
Lysine succinylation is a conserved and common post-translational modification across 
tissues [117–119]. Desuccinylation has been implicated in numerous metabolic signaling 
pathways. The electron transport chain CII subunits, succinate dehydrogenase (ubiquinone) 
flavoprotein (SDHA), and Succinate dehydrogenase (ubiquinone) iron-sulfur subunit 
(SDHB), are targets of SIRT5 desuccinylation [117]. Desuccinylation of HMGCS2 (3-
hydroxy-3-methylglutaryl-CoA synthase 2) activates its enzymatic activity [118]. PDH is 
also a target of desuccinylation by SIRT5 that inactivates PDH [117]. ROS regulation is 
controlled by desuccinylation of SOD1, which increases it activity [120]. Lysine 
malonylation appears to play a role in glucose metabolism by responding to glucose levels 
and may regulate glycolytic and gluconeogenic pathways. In liver tissue of mice lacking 
SIRT5, protein malonylation increased and glycolytic flux was significantly diminished 
[119], providing evidence for a role of SIRT5 in regulating malonylation. Lysine 
glutarylation appears to be metabolically regulated through the actions of SIRT5 
deglutarylation. Protein glutarylation changes in response to feed-fast states and targets the 
rate-limiting mitochondrial enzyme in the urea cycle, carbamoyl phosphate synthase 1 
(CPS1), with glutarylation inhibiting its activity. CPS1 was also identified as a target for 
deglutarylation by SIRT5. Taken together, lysine acylation in its early stages of 
characterization appears to regulate diverse mitochondrial metabolic processes through 
protein post-translational processing [121].
ADP-Ribosylation
ADP-ribosylation, or poly(ADP-ribosylation) (PARylation) is a reversible PTM that requires 
NAD+ as a cofactor. The enzymes poly(ADP-ribose) polymerases (PARPs), also known as 
ADP-ribosyltransferases (ARTs) according to their transferase activity [122], act by cleaving 
NAD+ into nicotinamide (NAM) and ADP-ribose (ADPR) and transferring the ADPR onto 
select amino acid residues of substrate protein side chains or onto another ADPR. By adding 
subsequent ADPR units, they can build an ADPR polymer, or poly(ADP-ribose) (PAR), on 
the target protein. Multiple PARPs have been identified [122], with PARP-1 activity 
responsible for the majority of PARylation in the cell [123]. PARylation has been well 
described in the nucleus and cytosol, and nuclear PARylation has a well-defined regulatory 
role in DNA repair, transcription and cell division [124]. PARPs are activated by DNA and 
oxidative damage, increased calcium, interaction with phosphorylated ERK2, and reversible 
acetylation [125–130]. Mechanisms of PARP inhibition include auto-PARylation, 
phosphorylation by protein kinase C, and sumoylation [131–133]. PARylation in the cell is 
controlled by the enzymes Poly (ADP-Ribose) glycohydrolase (PARG) and ADP-ribosyl 
protein hydrolase-3 (ARH-3), which rapidly degrade PAR [134, 135].
Attention has been recently directed at PARylation as an important PTM in regulating 
mitochondrial function. However, it remains under debate whether there exists a 
mitochondria-specific PARP and localized mechanism of action, or whether the effects of 
PARylation is exerted on mitochondrial proteins via nuclear or cytosolic PARP activity (e.g. 
PARP-1). Recent comprehensive reviews on the role of PARylation in mitochondria have 
been published [136–138] which discuss the cumulative body of research and ongoing 
investigation into mitochondria-relevant PARylation.
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It is clear that PARP-1 activation and PARylation negatively affect mitochondrial energy 
metabolism. Interestingly, PARP-1 can travel outside the nucleus and bind to mitochondria, 
resulting in inhibition of OXPHOS activity and energy depletion, via an interaction with 
hexokinase [139]. Experimental overexpression of mitochondria-targeted PARP-1 led to 
increased PARylation of intra-mitochondrial proteins and reduction in mitochondrial 
respiratory activity and energy depletion [140]. Activation of PARP-1 in cell culture lead to 
decreased mitochondrial respiration, cellular energy equivalents, mitochondrial membrane 
collapse and mitochondria-induced cell death, and was reversed with PARP-1 inhibition 
[141].
Both PARylation and deacetylation rely on NAD+ metabolism, and PARP activation leads to 
depletion of NAD+ [142]. Further, PARPs have been found to be targets of acetylation [130, 
143]. Thus, an important consideration is whether there is a metabolic regulatory interaction 
between PARylation and acetylation [144]. Indeed, recent studies have provided evidence of 
such an interaction. Activation of PARP-1 in cardiomyocytes and failing mouse hearts 
resulted in depletion of NAD and inhibition of SIRT1 and lead to cell death [145]. 
Conversely, deletion of PARP-1 lead to increased NAD+, activated SIRT1 and outcome 
measures consistent with enhanced mitochondrial function in brown adipose and muscle 
tissue [146]. Blocking PARP-1 in diabetic retinal endothelial cells prevented associated 
downregulation of SIRT3 and protected the cells from oxidative damage [147].
Conclusion
The rapid and recent increase in knowledge of protein post-translational processing 
mechanisms and their known mitochondrial targets has lead to a tremendous amount of new 
information on the mitochondrial orchestration of cellular energy and metabolism. Certainly, 
the functional significance of many of these post-translational modifications in the 
mitochondria in regards to their impact of in the pathophysiology of disease remains under 
intense investigation. However, it is evident that protein signaling via reversible protein 
modifications is widely and extensively used in mitochondria to respond to nutrient and 
redox status. Given the fundamental role of mitochondria in providing energy and regulating 
metabolic homeostasis of the cell, and the close link between mitochondrial dysfunction and 
disease, ongoing investigations will likely continue to yield clues to functional significance. 
Mitochondrial protein modifications continue to show promise for use as modifiable 
mitochondrial targets for therapies aimed at metabolic regulation.
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Figure 1. 
Overview of oxidative phosphorylation (OXPHOS) enzyme complexes of the electron 
transport chain (ETC) and flow of electrons through the system coupled to ATP generation 
(chemiosmotic coupling). Post-translational modification of ETC proteins is an important 
regulatory mechanism in mitochondria, and is used to respond to changes in metabolism and 
energy requirements. MOM = mitochondrial outer membrane; IMS = intermembrane space; 
MIM = mitochondrial inner membrane; CI = NADH dehydrogenase; CII = ubiquinol 
cytochrome c reductase; CIII = succinate dehydrogenase; CIV = cytochrome c oxidase; CV 
= ATP synthase; Q = coenzyme Q; C = cytochrome c
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Figure 2. 
Reversible Lysine Acetylation. Mitochondrial protein lysine acetylation is regulated by the 
NAD+-dependent deacetylase, SIRT3. SIRT3 responds to mitochondrial energy and redox 
state to target proteins that, in turn, signal changes in cellular function. Ac-CoA = Acetyl-
CoA; FAO = fatty acid oxidation; ? = no identified acetyltransferase enzyme; Ac-K = acetyl-
lysine; K = lysine; NAM = nicotinamide; ADPR = ADP-Ribose; ROS = reactive oxygen 
species; mPTP = mitochondrial permeability transition pore
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